Related Experiment Video

Updated: Jul 14, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity

J Van Heusden1, R Van Ginckel, H Bruwiere

  • 1Department of Oncology Discovery Research, Johnson & Johnson Pharmaceutical Research & Development, Turnhoutseweg 30, B-2340 Beerse, Belgium.

British Journal of Cancer
|March 1, 2002
PubMed

Insights

A new drug, R116010, effectively inhibits all-trans-retinoic acid metabolism, a key factor in cancer resistance. This potent and selective inhibitor enhances the anticancer effects of all-trans-retinoic acid, showing promise for cancer treatment.

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Metabolism

Background:

  • All-trans-retinoic acid (ATRA) is a potent anticancer agent but its clinical use is limited by toxicity and resistance.
  • Increased metabolism of ATRA is a primary mechanism driving resistance to this drug.
  • Inhibitors of ATRA metabolism represent a potential strategy to overcome treatment resistance and enhance efficacy.

Purpose of the Study:

  • To characterize a novel compound, R116010, as a potent and selective inhibitor of all-trans-retinoic acid metabolism.
  • To evaluate the in vitro and in vivo efficacy of R116010 as a potential anticancer agent.
  • To determine if R116010 can enhance the antiproliferative activity of all-trans-retinoic acid.

Main Methods:

  • In vitro assessment of R116010's inhibition of all-trans-retinoic acid metabolism in T47D cells using IC(50) values.
  • Evaluation of R116010's selectivity by testing its effect on other cytochrome P450-mediated reactions.
  • In vitro cell proliferation assays using T47D cells to assess the combined effects of R116010 and all-trans-retinoic acid.
  • In vivo studies using murine TA3-Ha mammary tumors to assess the antitumour activity of R116010.

Main Results:

  • R116010 demonstrated potent inhibition of all-trans-retinoic acid metabolism in vitro with an IC(50) of 8.7 nM.
  • R116010 exhibited selectivity as an inhibitor, with minimal impact on other cytochrome P450-mediated reactions.
  • R116010 alone had no effect on cell proliferation but significantly enhanced the antiproliferative activity of all-trans-retinoic acid in a dose-dependent manner.
  • In vivo, R116010 significantly inhibited the growth of mammary tumors at low doses (0.16 mg kg(-1)).

Conclusions:

  • R116010 is a highly potent and selective inhibitor of all-trans-retinoic acid metabolism.
  • R116010 potentiates the biological activity and anticancer effects of all-trans-retinoic acid.
  • R116010 exhibits significant antitumour activity and represents a novel anticancer drug candidate with a unique mechanism of action.

More Related Videos

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...